Condition (MeSH)
Microvascular Angina
ClinicalTrials.gov lists 108 trials for Microvascular Angina or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
108 of the 108 trials are tagged with Microvascular Angina itself; the rest are tagged with a narrower condition beneath it.
When did Microvascular Angina trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 7 |
| 2024 | 11 |
| 2023 | 15 |
| 2022 | 10 |
| 2021 | 9 |
| 2020 | 8 |
| 2019 | 5 |
| 2018 | 7 |
| 2017 | 1 |
Showing 10 of 24 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 5 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 14 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 45 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Microvascular Angina trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 15 |
| Not applicable | 35 |
| Observational | 47 |
How many Microvascular Angina trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 22 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 13 |
| Completed | 33 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Microvascular Angina trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CoreAalst BV | 2 |
| Genetesis Inc. | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
Which drugs are being tested for Microvascular Angina? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NEBIVOLOL | 3 |
| Ranolazine | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 2% Diltiazem | 2 |
| Acupuncture | 1 |
| Brenzavvy (bexagliflozin), 20 mg Oral Tablet | 1 |
| Ticagrelor (Brilique) 90 | 1 |
| Kuangxiong Aerosol | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Microvascular Angina trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| angina pectoris | 2 | 1 |
| COVID-19 pneumonia | 1 | 1 |
| atrial fibrillation | 1 | 1 |
| bradycardia | 1 | 1 |
| coronary artery dissection | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Microvascular Angina? (79)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial. | Circulation | 2024 | Yes |
| "The INOCA-IT: Rationale and design of a multicenter registry investigating ischemia in patients with non-obstructive coronary artery (INOCA) disease in Italy". | International journal of cardiology | 2024 | Yes |
| Coronary microvascular dysfunction assessment: A comparative analysis of procedural aspects. | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions | 2024 | Yes |
| Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial. | Circulation | 2024 | Yes |
| Heart-brain microvascular MRI study: protocol for a multicentre, observational, cohort study in the UK assessing associations between small vessel disease of the heart and brain. | BMJ open | 2024 | Yes |
Showing 5 of 79 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.